Terns Pharmaceuticals, Inc. corporate insiders have only been selling lately: three insiders sold off about $7.1 million of stock over 12 months, with no open-market purchases.
Selling on its own is common and often pre-planned (10b5-1 plans, taxes, diversification), so it matters more when it is unusually heavy or broad.
No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | Kuriakose Emil | Executive Officer | Sell | 942 | $52.75 | $50K | SEC |
| Mar 17, 2026 | Burroughs Amy L. | CEO | Sell | 2,770 | $47.30 | $131K | SEC |
| Mar 17, 2026 | Burroughs Amy L. | CEO | Sell | 11,813 | $46.57 | $550K | SEC |
| Feb 18, 2026 | Burroughs Amy L. | CEO | Sell | 4,083 | $39.80 | $163K | SEC |
| Feb 18, 2026 | Burroughs Amy L. | CEO | Sell | 8,159 | $39.22 | $320K | SEC |
| Feb 18, 2026 | Burroughs Amy L. | CEO | Sell | 2,341 | $38.07 | $89K | SEC |
| Jan 16, 2026 | Burroughs Amy L. | CEO | Sell | 61,228 | $37.02 | $2.3M | SEC |
| Jan 16, 2026 | Burroughs Amy L. | CEO | Sell | 7,521 | $37.53 | $282K | SEC |
| Jan 6, 2026 | Burroughs Amy L. | CEO | Sell | 71,339 | $38.10 | $2.7M | SEC |
| Jan 6, 2026 | Kuriakose Emil | Executive Officer | Sell | 955 | $38.36 | $37K | SEC |
| Jan 6, 2026 | Kuriakose Emil | Executive Officer | Sell | 200 | $39.60 | $8K | SEC |
| Nov 5, 2025 | Quigley Jill M. | Director | Sell | 24,520 | $18.00 | $441K | SEC |
| Oct 2, 2025 | Kuriakose Emil | Executive Officer | Sell | 944 | $7.85 | $7K | SEC |
| Jul 3, 2025 | Kuriakose Emil | Executive Officer | Sell | 853 | $4.27 | $4K | SEC |
| Jun 30, 2025 | Gengos Andrew | CFO | Buy | 5,000 | $3.93 | $20K | SEC |
In the last 12 months Terns Pharmaceuticals, Inc. insiders made open-market purchases worth about $0 and sales worth about $7.1 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in TERN was filed on 2026-04-02.
No congressional trades in TERN were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).